UTv Videos

"We're asking the bladder to come have a seat and to give voice to surgical choice," says Wayne Kuang, MD.

"There's a number of emerging modalities in the primary focal ablation space that are in trial at this time," says Kara L. Watts, MD.

As the year comes to a close, we revisit some of this year’s top content on benign prostatic hyperplasia.

"We're excited about the science behind it, but we're also excited for our patients that if they can have access to this, maybe we can delay or completely avoid radical cystectomy or further aggressive treatments," says Shreyas S. Joshi, MD, MPH.

“I think there's a lot to be done and combination therapies, other drugs that can be instilled into this device. It's a bright future,” says Siamak Daneshmand, MD.

"We're trying to be the coach to our patients," says Wayne Kuang, MD.

“In some ways, it can be used to help if you want to get a biopsy to prove or confirm—it can be used to help detect in that range, too,” says Michael S. Cookson, MD, MMHC, FACS.

“In that randomized trial, we have level 1 evidence showing that patients have less pain and faster return of bowel function when you work at low pressure,” says Ronney Abaza, MD.

"There are only 2 major organs you can't transplant: the brain and the bladder. So let's take care of the bladder," says Wayne Kuang, MD.

“Some of the main implications for urologists is that the risk adapted utilization of BCG, which has been implemented as guidelines, should continue,” says Madison M. Wahlen.

“The other aspects of the waivers and the things that remain in flux and are not fully fleshed out are going to be things like interstate telehealth,” says Juan J. Andino, MD, MBA.

"What's unique about our conference is the focus is not on just showcasing what our institute has to offer; the real focus is on networking and collaborating with the top institutes in the nation," says Raveen Syan, MD, FPMRS.

"The main benefit, I guess, for Aquablation over TURP, is the fact that the sexual side effects are much better when compared to TURP," says Mohamad Baker Berjaoui, MD.

“We really want to understand whether by using this beta emitter, together with the combination of cabazantinib and the nivolumab, we're getting better outcomes than we would expect with the doublet alone,” says Eric Jonasch, MD.

Chad Ellimoottil, MD, MS, details specific concerns surrounding the future of telehealth as Congress weighs the decision to extend flexibilities.

“What we've been working on is a giant 30,000 patient database study using the National Cancer Database to see exactly what the rates are of upstaging and downstaging for these larger kidney tumors,” says Taylor Goodstein, MD.

“Without the ability to do new patient telehealth, by definition, it's really hard to impact access to care,” says Juan J. Andino, MD, MBA.

"We found that patients whose care was impacted by shortages did not have statistically significantly worse recurrence outcomes compared to patients whose care was not impacted by shortages," says Madison M. Wahlen.

"We found that with a 5-year Kaplan-Meier survival analysis that patients with varicocele had worse outcomes than patients without varicocele," says Muhammed A. Moukhtar Hammad, MBBCh.

“It's very rare that a patient has to stay in the hospital overnight after a robotic surgery as long as they're getting a good quality operation,” says Ronney Abaza, MD, FACS.

"I think that there's been a lot of positive momentum to continue coverage for telehealth without geographic restrictions, to continue coverage for phone calls, but there's still some uncertainty as to whether or not that's going to be passed, even though there is a lot of optimism for it," says Chad Ellimoottil, MD, MS.

“It encompasses and contains the miTNM, PROMISE, PRIMARY, RECIP, PSMA-RADS, and E-PSMA concept and criteria all together,” says Jeremie Calais, MD, PhD.

"What's important here is that there's an increased public interest in this vaginal estrogen therapy," says Elia Abou Chawareb, MD.

“With the Expanded Access Program, it is an opportunity for patients to receive the drug in real-world practice,” says Sarah P. Psutka, MD, MSc.

"Overall, our trial shows promising early oncological efficacy with a favorable toxicity profile," says Gal Wald, MD.

“I think having the ability to monitor patients with imaging and using things like PSMA-PET is good, but yet we're we sometimes have pitfalls with PSMA-PET too,” says Michael Cookson, MD.

"I think the precision of Aquablation helps significantly with improving the results," says Mohamad Baker Berjaoui, MD.

ProstACT GLOBAL is assessing the safety and efficacy of 177Lu-TLX591 plus SOC vs SOC alone in patients with mCRPC.

"We wanted to see if medical recommendations for vaginal estrogen for postmenopausal women for symptom correction have a correlation with rising interest [among patients]," says Elia Abou Chawareb, MD.

“Physicians are spending, depending on how much they utilize it, 20% to 30% less time on nights and weekends,” says Ernest A. Morton, MD, MBA, MS.